Podcast Episodes
Back to Search
AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts
Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulc…
1 year, 5 months ago
Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers
He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.
1 year, 5 months ago
The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database
CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been combined wi…
1 year, 5 months ago
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease th…
1 year, 6 months ago
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good …
1 year, 6 months ago
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies …
1 year, 6 months ago
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
1 year, 6 months ago
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out imman…
1 year, 6 months ago
Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials
Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital dermatology, and invit…
1 year, 6 months ago
HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable
From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development, and gives a…
1 year, 6 months ago